Skip to main content
SpringerLink
Log in

Erythropoietin and uremic platelet aggregation in vivo and in vitro

  • Original
  • Published:
International Journal of Clinical and Laboratory Research

Abstract

Erythropoietin treatment is known to correct anemia and to improve hemostasis. Since platelets may contribute to thromboembolic complications, we assessed platelet aggregation in whole blood and platelet-rich plasma from chronically hemodialyzed patients treated with erythropoietin and evaluated in vitro effects of this drug on aggregatory responses of uremic and normal platelets. Recombinant human erythropoietin was given to uremic patients at a dose of 2.000 IU subcutaneously three times a week. Platelet aggregation in whole blood and platelet-rich plasma was induced by collagen, ADP, arachidonic acid, and ristocetin. In uremic patients, erythropoietin therapy resulted in an enhancement of platelet sensitivity to various agonists, particularly in platelet-rich plasma, reaching values comparable to those of healthy volunteers. In vitro studies we were unable to show any direct effect of erythropoietin, used at concentrations that occurred post intravenous administration, on platelet aggregation both in whole blood and in platelet-rich plasma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sundal E, Kaeser U. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in an European multicentre study of 150 haemodialysis dependent patients. Nephrol Dial Transplant 1989;4:979.

    PubMed  CAS  Google Scholar 

  2. Teramura M, Mizoguchi H. The effect of cytokines on the ploidy of megakaryocytes. Int J Cell Cloning 1990;8:245.

    Article  PubMed  CAS  Google Scholar 

  3. Kaupke CJ, Butler GC, Varizi ND. Effect of recombinant human erythropoietin on platelet production in dialysis patients. J Am Soc Nephrol 1993;3:1672.

    PubMed  CAS  Google Scholar 

  4. Cases A, Escolar R, Reverter JC, Ordinas A, Lopez-Pedret J, Revert L, Castillo R. Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int 1992;42:668.

    PubMed  CAS  Google Scholar 

  5. Taylor JE, Belch JJF, McLaren M, Henderson IS, Steward WK. Effects of erythropoietin therapy and withdrawal on blood coagulation and fibrolysis in hemodialysis patients. Kidney Int 1993;44:182.

    PubMed  CAS  Google Scholar 

  6. Edmunds ME, Walls J, Tucker B. Seizures in hemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 1989;4:1065.

    PubMed  CAS  Google Scholar 

  7. Sundal E, Businger J, Kappeler A. Treatment of transfusion-dependent anaemia of chronic renal failure with recombinant human erythropoietin. Nephrol Dial Transplant 1991;6:955.

    PubMed  CAS  Google Scholar 

  8. Fraser JK, Tan AS, Lin FK, Berridge MV. Expression of specific high-affinity binding sites for erythropoietin on rat and mouse megakaryocytes. Exp Hematol 1989;17:10.

    PubMed  CAS  Google Scholar 

  9. Malyszko J, Urano T, Knofler R, Taminato A, Yoshimi T, Takada Y, Takada D. Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. Thromb Res 1994;75:569.

    Article  PubMed  CAS  Google Scholar 

  10. Neumayer HH, Brockmoller J, Fritschka E, Roots I, Scigalla P, Wattenberg M. Pharmacokinetics of recombinant human erythropoietin after s.c. administration and in long-term i.v. treatment in patients on maintenance hemodialysis. Contrib Nephrol 1989; 76:131.

    PubMed  CAS  Google Scholar 

  11. Wilsoncroft PS, Lofts FJ, Griffits RJ, Moore PK. The effect of 6-oxo-PGE1 on human platelet aggregation in whole blood in vitro. J Pharm Pharmacol 1985;37:139.

    PubMed  CAS  Google Scholar 

  12. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1964;194:927.

    Article  Google Scholar 

  13. Hellem AJ. The adhesiveness of human blood platelets in vitro. Scand J Clin Lab Invest 1960;12 [Suppl]:51.

    Google Scholar 

  14. Quick AJ. The physiology and pathology of haemostasis. London; Kimpton, 1951.

    Google Scholar 

  15. Moia M, Mannucci PM, Vizotto L, Casati M, Ponticelli C. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet II:1987:1227.

    Article  Google Scholar 

  16. Gordge MP, Leaker B, Patel A, Oviasu E, Cameron JS, Neild GH. Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatic activation. Thromb Res 1990;57:171.

    Article  PubMed  CAS  Google Scholar 

  17. Geet C van, Hauglustaine D, Verresen L, Vanrusselt M. Hemostatic effects of recombinant human erythropoietin in chronic hemodialysis patients. Thromb Haemost 1989;61:117.

    PubMed  Google Scholar 

  18. Huraib S, Al-Momen AK, Gader AMA, Mitwalli A, Sulimani F, Abu-Aisha H. Effect of recombinant human erythropoietin (rHuEPO) on the hemostatic system in chronic hemodialysis patients. Clin Nephrol 1991;36:252.

    PubMed  CAS  Google Scholar 

  19. Malyszko J, Mazerska M, Malyszko JS, Pawlak K, Azzadin A, Mysliwiec M, Buczko W. Serotonergic mechanisms are involved in the hemostatic action of erythropoietin in uremic patients. Int J Clin Lab Res 1993;23:42.

    PubMed  CAS  Google Scholar 

  20. Coller BS, Gralnick HR. Studies on the mechanism of ristocetin-induced platelet agglutination. Effects of structural modification of ristocetin and vancomycin. J Clin Invest 1977;60:302.

    Article  PubMed  CAS  Google Scholar 

  21. Houdrille P, Gralnick HR, Heilmann E, Derlon A, Farrer AM, Vezon G, Nurden AT. Von Willebrand factor bound to glycoprotein Ib is cleared from the platelet surface after platelet activation by thrombin. Blood 1992;79:2011.

    Google Scholar 

  22. Berndt MC, Du X, Booth WJ. Ristocetin-dependent reconstitution of binding of von Willebrand factor to purified human platelet membrane glycoprotein Ib-IX complex. Biochemistry 1988; 27:633.

    Article  PubMed  CAS  Google Scholar 

  23. Stibbe J, Kirby E. The influence of haemaccel fibrinogen and albumin on ristocetin-induced platelet aggregation. Relevance to the quantitative measurement of the ristocetin cofactor. Thromb Res 1976;8:151.

    Article  PubMed  CAS  Google Scholar 

  24. Hamilton KK, Sims PJ. Changes in cytosolic Ca2+ associated with von Willebrand factor release in human endothelial cell exposed to histamine. J Clin Invest 1987;79:600.

    PubMed  CAS  Google Scholar 

  25. Akizawa T, Kinugasa E, Ketada T, Koshikawa S. Effects of recombinant human erythropoietin and correction of anemia on platelet function in hemodialysis patients. Nephron 1991; 58:400.

    PubMed  CAS  Google Scholar 

  26. Taylor JE, Belch JJF, McLaren IS, Stewart WK. Effects of nifedipine on changes in fibrinogen and von Willebrand factor in haemodialysis patients treated with recombinant erythropoietin. Blood Coagul Fibrinol 1995;6:100.

    CAS  Google Scholar 

  27. Tomura S, Nakamura Y, Deguchi Y, Deguchi F, Chida Y. Enhanced blood coagulation—fibrinolysis in chronic hemodialysis patients receiving recombinant erythropoietin treatment. Proceedings of the 27th Annual Congress of the EDTA-ERA: 1990; Vienna. Book of abstracts. Sweden: Rahmsi Lund, 1990; 260.

    Google Scholar 

  28. Taylor JE, Belch JJF, Henderson IS, Stewart WK. Erythropoietin does not increase whole blood platelet aggregation in vitro. Nephrol Dial Transplant 1993;8:1291.

    PubMed  CAS  Google Scholar 

  29. Eknoyan G, Brown CH. Biochemical abnormalities of platelets in renal failure. Am J Nephrol 1981;1:17.

    Article  PubMed  CAS  Google Scholar 

  30. DeClerck P. Effects of serotonin on platelet and blood vessels. J Cardiovasc Pharmacol 1991;17 [Suppl 5]:S1.

    Google Scholar 

  31. Goodnough L, Rudnick S, Price T. Increased pre-operative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med 1989;321:1163.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nephrology Department, Bialystok Medical School, Zurawia 14, 15-540, Bialystok, Poland

    J. S. Malyszko, J. Malyszko, K. Pawlak & M. Mysliwiec

Authors
  1. J. S. Malyszko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Malyszko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Pawlak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Mysliwiec
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Malyszko, J.S., Malyszko, J., Pawlak, K. et al. Erythropoietin and uremic platelet aggregation in vivo and in vitro. Int J Clin Lab Res 26, 199–202 (1996). https://doi.org/10.1007/BF02592982

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02592982

Key words

Search

Navigation